Imaxio has signed an option for a
license agreement with Merial, the animal health division of Sanofi, to develop an
animal health vaccine based on Imaxio's immune-enhancing IMX313 technology.
Merial will
conduct an internal review of the IMX313 technology for 12–18 months, and
depending on the results, will sign a license agreement. Details of the vaccine
candidate and the financial terms of the agreement have not yet been
disclosed.
The aim of IMX313, Imaxio's proprietary technology for antigen
re-engineering, is to significantly enhance the immune response and the
efficiency of vaccines with which it is used. In response to the challenge of
certain ineffiacious vaccine candidates, IMX313 is a high-potential solution,
which would not only enable the dose to be reduced, but also the number of
revaccinations needed, according to the company.
No comments:
Post a Comment